DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Bioactive CompoundsBioactive Compounds
  4. /MAPK/ERK PathwayMAPK/ERK Pathway
  5. /p38 MAPKp38 MAPK
  6. /PamapimodPamapimod
Chemical structure of CAS 449811-01-2

Pamapimod

CAS No.449811-01-2
MDL No.MFCD25976551
MFC19H20F2N4O4
MW406.40
InChI KeyJYYLVUFNAHSSFE-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Pamapimod is a pyridopyrimidine compound with an 8-methylpyrido[2,3-d]pyrimidin-7(8H)-one core, substituted at position 2 with a (1,5-dihydroxypentan-3-yl)amino group and at position 6 with a 2,4-difluorophenoxy group. It is a potent inhibitor of MAPK, used in the treatment of rheumatoid arthritis. It functions as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor and an antirheumatic drug. It also exhibits properties of an aromatic ether, difluorobenzene, aromatic amine, secondary amino compound, primary alcohol, and diol.

CAS No.449811-01-2
Product NamePamapimod

Biological Targets

MAPK14
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis.

Arthritis research & therapy • Vol. 12, Issue 3 • 2010
PMID: 20509880PMC: PMC2911895DOI: 10.1186/ar3038

A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.

Journal of clinical pharmacology • Vol. 50, Issue 9 • 2010
PMID: 20100913DOI: 10.1177/0091270009357433

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.

Annals of the rheumatic diseases • Vol. 69, Issue 2 • 2010
PMID: 19357113DOI: 10.1136/ard.2008.104802

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

Journal of medicinal chemistry • Vol. 53, Issue 6 • 2010
PMID: 19950901DOI: 10.1021/jm9012906

Documentation

Similar Products

  • R-1487

    CAS No.449811-92-1

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact